Market Place
Sourcing Support
Evaxion Shows AI-Immunology Platform Scalability In Glioblastoma
19 Apr 2026 //
FIRSTWORD PHARMA
Evaxion Concludes Annual General Meeting
16 Apr 2026 //
FIRSTWORD PHARMA
Evaxion Wraps Final Patient Visit in EVX-01 Phase 2 Extension
07 Apr 2026 //
GLOBENEWSWIRE
Evaxion Unveils AI Polio Vaccine at World Vaccine Congress
30 Mar 2026 //
GLOBENEWSWIRE
Notice To Convene Evaxion`s Annual General Meeting
19 Mar 2026 //
GLOBENEWSWIRE
Evaxion To Present New Data At AACR Annual Meeting
17 Mar 2026 //
GLOBENEWSWIRE
Evaxion Plans To File 2025 Annual Report Later Today
05 Mar 2026 //
GLOBENEWSWIRE
Evaxion Unveils Business Update And 2025 Financial Results
05 Mar 2026 //
GLOBENEWSWIRE
Evaxion Announces Business Update, 2025 Financials on March 5
02 Mar 2026 //
GLOBENEWSWIRE
Evaxion Expands Ai-Immunology Platform Into Autoimmune Diseases
13 Jan 2026 //
GLOBENEWSWIRE
Evaxion To Showcase 2026 Milestones At Biotech Conference
07 Jan 2026 //
GLOBENEWSWIRE
Evaxion provides update on MSD collab For Gonorrhea EVX-B2
20 Dec 2025 //
FIERCE BIOTECH
Evaxion Presents EVX-04 Data for Acute Myeloid Leukemia at ASH
06 Dec 2025 //
GLOBENEWSWIRE
Evaxion Reports Favorable Results For Key Antigens In CMV Vaccine
20 Nov 2025 //
GLOBENEWSWIRE
Evaxion Announce 2026 Financial Calendar
12 Nov 2025 //
GLOBENEWSWIRE
Evaxion Shows Immune Data From AI-Designed Cancer Vaccine Trial
07 Nov 2025 //
GLOBENEWSWIRE
Evaxion Boosts R&D Pipeline With Ai-Designed Cancer Vaccine
03 Nov 2025 //
GLOBENEWSWIRE
Evaxion To Unveil Business Update And Q3 2025 Financials
31 Oct 2025 //
GLOBENEWSWIRE
Evaxion Extends Cash Runway To 2nd Half Of 2027 With $7.2M Raise
30 Oct 2025 //
GLOBENEWSWIRE
Evaxion Names Dr. Helen Tayton-Martin CEO
27 Oct 2025 //
GLOBENEWSWIRE
Evaxion’s AI Vaccine EVX-01 Hits 75% ORR in Ph2 Cancer
17 Oct 2025 //
GLOBENEWSWIRE
Evaxion Stock Slips On Phase 2 Cancer Vax Data
17 Oct 2025 //
FIERCE BIOTECH
Evaxion To Showcase Phase 2 Ai-Designed Cancer Vaccine Data
13 Oct 2025 //
GLOBENEWSWIRE
Evaxion Expands AI-Immunology Platform With Vaccine Design Module
08 Oct 2025 //
GLOBENEWSWIRE
Evaxion To Unveil Ai-Designed Cancer Vaccine Biomarker Data
03 Oct 2025 //
GLOBENEWSWIRE
Evaxion Out-Licenses Vaccine Candidate EVX-B3 To MSD
25 Sep 2025 //
GLOBENEWSWIRE
Evaxion to Present at Multiple Conferences in H2 2025
27 Aug 2025 //
GLOBENEWSWIRE
Evaxion Reports Q2 2025 Financial Results and Business Update
14 Aug 2025 //
GLOBENEWSWIRE
Evaxion`s Business Update and Q2 2025 Financial Results
11 Aug 2025 //
GLOBENEWSWIRE
Evaxion to Unveil 2-Year Data from EVX-01 Cancer Vaccine Trial
25 Jul 2025 //
GLOBENEWSWIRE
Evaxion and EIB Agree to Convert Debt into Equity
11 Jul 2025 //
GLOBENEWSWIRE
Evaxion optimizes Executive Management for AI-Immunology
01 Jul 2025 //
GLOBENEWSWIRE
Evaxion adds new vaccine program for Group A Streptococcus
25 Jun 2025 //
GLOBENEWSWIRE
Evaxion Receives Grant Funding to Design New Polio Vaccine
03 Jun 2025 //
GLOBENEWSWIRE
Evaxion Updates Business and Q1 2025 Financial Results
27 May 2025 //
GLOBENEWSWIRE
Evaxion to announce Q1 2025 results on May 27, 2025
23 May 2025 //
GLOBENEWSWIRE
Evaxion Begins Dosing in AI-Cancer Vaccine EVX-01 Phase 2 Trial
22 May 2025 //
GLOBENEWSWIRE
Evaxion presents EVX-01 data at AACR Annual meeting
28 Apr 2025 //
GLOBENEWSWIRE
Evaxion to present at World Vaccine Congress
10 Apr 2025 //
GLOBENEWSWIRE
Evaxion updates business and 2024 financial Results
01 Apr 2025 //
GLOBENEWSWIRE
Evaxion to announce 2024 financial results on April 1, 2025
27 Mar 2025 //
GLOBENEWSWIRE
Evaxion to unveil phase 2 data for cancer vaccine at AACR Meeting
25 Mar 2025 //
GLOBENEWSWIRE
Evaxion to present at numerous upcoming conferences
04 Mar 2025 //
GLOBENEWSWIRE
Evaxion extends phase 2 trial with cancer vaccine EVX-01
25 Feb 2025 //
GLOBENEWSWIRE
Nasdaq Confirms Evaxion Compliance, Withdraws Delisting Notice
14 Feb 2025 //
GLOBENEWSWIRE
Evaxion announces closing of $10.8 million public offering
31 Jan 2025 //
GLOBENEWSWIRE
Evaxion announces pricing of $10.8 million public offering
30 Jan 2025 //
GLOBENEWSWIRE
Evaxion Granted 180-Day Nasdaq Compliance Extension For Restoration
28 Jan 2025 //
GLOBENEWSWIRE
Evaxion Completes Major Phase In Cancer Vaccine Development
15 Jan 2025 //
GLOBENEWSWIRE
Evaxion announces completion of ADS ratio change
14 Jan 2025 //
GLOBENEWSWIRE
Evaxion announces extension to Jan 14 of plan to ADS ratio change
10 Jan 2025 //
GLOBENEWSWIRE
Evaxion announces plan to implement ADS ratio change
30 Dec 2024 //
GLOBENEWSWIRE
Evaxion Seeks Agreement with EIB to Convert Debt to Equity
17 Dec 2024 //
GLOBENEWSWIRE
Evaxion Develops AI-Derived Precision Cancer Vaccine Concept
12 Dec 2024 //
GLOBENEWSWIRE
Evaxion Announces Milestones Reflecting Strong Strategy Execution
09 Dec 2024 //
GLOBENEWSWIRE
Evaxion Appeals Nasdaq Delisting, Remains Committed to Listing
13 Nov 2024 //
GLOBENEWSWIRE
Evaxion Reports Positive Data for CMV Vaccine EVX-V1
12 Nov 2024 //
GLOBENEWSWIRE
Evaxion announces business update and Q3 2024 financial results
31 Oct 2024 //
GLOBENEWSWIRE
Evaxion to Update Business and Q3 2024 Financials on Oct. 31
28 Oct 2024 //
#N/A
Evaxion`s AI-Immunology Platform Validated In Clinical Trials
09 Oct 2024 //
GLOBENEWSWIRE
